- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01350154
Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients
Does Modulation of the nNOS System in Patients With Muscular Dystrophy and Defect nNOS Signalling Affect Cardiac, Muscular or Cognitive Function?
This study is done to evaluate whether treatment with the drug sildenafil (Revatio®) can improve muscular, cardiac, cerebrovascular or cognitive function in patients with Beckers muscular dystrophy when compared to placebo (inactive medication). The study is based on the recent findings of an improved cardiac function in a mouse model of muscular dystrophy (Adamo et al 2010) and the previous findings of changed cognitive function in people with Becker dystrophy.
In muscular dystrophy, the cellular protein, dystrophin is affected. During normal conditions, the enzyme neuronal nitric oxide synthase (nNOS), which produce nitric oxide (NO), is attached to dystrophin. NO is important in normal vascular function in each of muscle, heart and brain by stimulating production of cyclic GMP. However, in muscular dystrophy with dystrophin deficiency, nNOS do not have the normal cellular anchor, resulting in decreased NO levels and subsequent reduced cyclic GMP production. Sildenafil inhibits degradation of cGMP thus prolonging and increasing a cGMP response. Such effects are the basis for use of sildenafil in pulmonary hypertension and erectile dysfunction. Current hypothesis: Sildenafil restores the cyclic GMP function affected in muscular dystrophy wit nNOS deficiency resulting in improved muscle, cardiac, cerebrovascular and cognitive function.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The current clinical trial including people with Becker's muscular dystrophy and established deficiency in muscular content of nNOS protein consist of three sub-studies focusing on each of muscle function, cardiac function and brain function. In muscular dystrophy the dystrophin cellular complex usually located to muscle cells, is disrupted resulting in a known reduced nNOS activity. The reduced nNOS leads to reduced cyclic GMP production. nNOS and cyclic GMP are involved in the vascular response in striate muscle, cardiac vessels as well as the cerebrovascular response to hypercapnia and regional activation. In muscular dystrophy, the is an affected muscular and cardiac function and in some patients a changed cognitive function in described. Whether such is related to a reduced nNOS function and subsequent cGMP production is not fully understood. Inhibition of cGMP degradation by inhibiting the cGMP degrading enzyme phosphodiesterase 5 (PDE5) using PDE5 inhibitors such as sildenafil may result in restoration of vascular responses.
The study is designed as a double blind, randomised, balanced, placebo-controlled cross-over study performed during a 10 week treatment period. The patients will receive 4 weeks of either sildenafil or placebo with a 2 week washout period in between treatments. The study out-come parameters will be performed on two consecutive days at baseline, 4 weeks and 10 weeks, at two collaborating centers, Rigshospitalet for muscle and cardiac parameters and Glostrup Hospital for cerebrovascular and cognitive parameters.
The primary endpoints relate to each sub-study, assessing and comparing individual changes from baseline and during placebo/sildenafil treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Neuromuscular Clinic and Research Unit, Dept. Neurology, Rigshospitalet,
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Muscular dystrophy with known deficiency in nNOS
- Reduced cardiac function (<50%) and/or reduced muscular function (MRC<4+)
- Stable dosing (> 3 month)of cardiovascular medication
- Signed informed consent
Exclusion Criteria:
- Recent (< 6 month) cerebral or cardiac stroke
- Use of nitrate containing compounds, alpha receptor blocking agents or potent CUP3A4 inhibitors.
- Intolerance or allergy to sildenafil, or intake of drugs not compatible with sildenafil intake
- Overuse of drugs or alcohol
- inclusion in other trials of experimental medication within last 30 days
- known epilepsy
- reduced liver function (ASAT >500U/l in 2 repeated measurements when corrected for increase in creatinkinase levels.
- non-arteriitis anterior ischemic optic neuropathy (NAION) with reduced vision
- contraindications for MRI scan (metal implants, claustrophobia)
- hypotension (<90 mmHg systolic at baseline)
- conditions, medical or psychosocial which makes the subject inclusion inadvisable
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sildenafil (Revation) 20 mg
This arm will receive sildenafil for 4 weeks followed by 2 weeks washout and 4 weeks placebo.
|
20 mg in gelatine capsules, oral, three times daily
Other Names:
|
EXPERIMENTAL: Placebo
This arm will receive placebo for 4 weeks followed by 2 weeks washout and 4 weeks sildenafil
|
Lactose monohydrate oral in gelatine capsules, 3 times daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in change from baseline to 4 week placebo/sildenafil treatment in handgrip test with concomitant ultrasound measurement of flow in the brachial artery
Time Frame: Baseline and 4 weeks treatment
|
Primary outcome for substudy 1
|
Baseline and 4 weeks treatment
|
Difference in changes from baseline to 4 week placebo/sildenafil treatment in resting cardiac end-diastolic volume measured by MRI
Time Frame: Baseline and 4 week treatment
|
Primary outcome for substudy 2
|
Baseline and 4 week treatment
|
Difference in changes from baseline to 4 week placebo/sildenafil treatment in cerebrovascular reactivity to CO2 inhalation and finger stimulation measured by BOLD fMRI
Time Frame: Baseline and 4 weeks treatment
|
Primary outcome for substudy 3
|
Baseline and 4 weeks treatment
|
Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in Cognitive function measured by Cambridge Neuropsychological Test Automated Battery (CANTAB)
Time Frame: Baseline and 4 weeks treatment
|
Primay outcome for substudy 3
|
Baseline and 4 weeks treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in 6 minutes walk test
Time Frame: Baseline and 4 weeks treatment
|
Substudy 1
|
Baseline and 4 weeks treatment
|
Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in max test, measured by O2 uptake during maximal exercise on bike
Time Frame: Baseline and 4 weeks treatment
|
Substudy 1
|
Baseline and 4 weeks treatment
|
Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in Quality of life by SF36
Time Frame: Baseline and 4 weeks treatment
|
Substudy 1
|
Baseline and 4 weeks treatment
|
Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in resting cardiac function measured by cardiac MRI
Time Frame: Baseline and 4 weeks treatment
|
Substudy 2. Evaluation of resting cardiac ejection fraction and end-systolic volume.
|
Baseline and 4 weeks treatment
|
Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in cardiac function during hand grip exercise measured by cardiac MRI
Time Frame: Baseline and 4 weeks treatment
|
Substudy 2. Cardiac volumes and ejection fraction during 1 minute repeated maximal force hand exercise will be measured.
|
Baseline and 4 weeks treatment
|
Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in cerebrovascular reactivity and blood flow
Time Frame: Baseline and 4 weeks treatment
|
Substudy 3. fMRI BOLD evaluation of visual stimulation, MRI angiography for arterial diameter, arterial spin labeling for evaluation of cerebral blood flow and blood volumen.
|
Baseline and 4 weeks treatment
|
Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in basic activity and metabolites of the brain
Time Frame: Baseline and 4 weeks treatment
|
Substudy 3.Resting state network by fMRI and metabolites in brain regions by MRI spectroskopy.
|
Baseline and 4 weeks treatment
|
Difference in changes from baseline to 4 weeks placebo/sildenafil treatment in cognitive function measured by paper and pen test battery
Time Frame: Baseline and 4 weeks treatment
|
Substudy 3. A paper and pen cognitive test battery will be applied, including Trail making A and B, Addenbrooke's Cognitive Examination, Symbol DIgital MOdality tests
|
Baseline and 4 weeks treatment
|
Difference in changes from baseline to 4 weeks treatment placebo/sildenafil in plasma levels of signalling molecules
Time Frame: Baseline and 4 weeks treatment
|
Substudy 3. From blood samples taken at baseline, 4 and 10 weeks, analysis of several signalling molecules relevant for cardiac and cerebrovascular function will be performed.
|
Baseline and 4 weeks treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: John Vissing, MD, DMSci, Neuromuscular Clinic and Research Unit, Dept. Neurology, Rigshospitalet
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Muscular Disorders, Atrophic
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Sildenafil Citrate
Other Study ID Numbers
- RHGLBMD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Becker Muscular Dystrophy
-
Virginia Commonwealth UniversityEdgewise Therapeutics, Inc.RecruitingMuscular Dystrophies | Becker Muscular Dystrophy | Muscular Dystrophy in Children | Muscular Dystrophy, BeckerUnited States, United Kingdom
-
Boston Children's HospitalNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingLimb-girdle Muscular Dystrophy | Neuromuscular; Disorder, Hereditary | Duchenne/Becker Muscular DystrophyUnited States
-
University Children's Hospital, ZurichUnknownDuchenne / Becker Muscular DystrophySwitzerland
-
Gaziosmanpasa Research and Education HospitalCompletedDuchenne or Becker Muscular DystrophyTurkey
-
ItalfarmacoCompletedDuchenne and Becker Muscular Dystrophy | Polycytemia VeraCanada
-
InCor Heart InstituteUniversity of Sao Paulo; Federal University of Minas GeraisCompletedMyocardial Fibrosis | Muscular Dystrophies
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedBecker Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy | Limb-Girdle Muscular DystrophyUnited States
-
University of North Carolina, Chapel HillNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedMuscular Dystrophies | Duchenne Muscular Dystrophy | Becker Muscular Dystrophy | Limb-Girdle Muscular DystrophyUnited States
-
IRCCS Eugenio MedeaRecruitingMuscular Dystrophies | Becker Muscular Dystrophy | Limb Girdle Muscular Dystrophy | Facio-Scapulo-Humeral DystrophyItaly
-
RSPR Pharma ABCompletedDuchenne Muscular Dystrophy | Becker Muscular DystrophySweden
Clinical Trials on Sildenafil
-
University of PennsylvaniaWalter Reed National Military Medical CenterRecruiting
-
Rambam Health Care CampusUnknown
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); PfizerCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedErectile DysfunctionSingapore
-
Northwestern UniversityCompletedHand Foot Skin ReactionUnited States
-
The Cleveland ClinicCompletedPulmonary Hypertension | Diffuse Parenchymal Lung DiseaseUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
iX Biopharma Ltd.Linear Clinical ResearchCompletedErectile DysfunctionAustralia
-
N4 Pharma UK Ltd.BDD Pharma LtdCompleted
-
University Hospital, GrenobleCompleted